Corcept Therapeutics Incorporated

CORT

US2183521028

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
22.8 ^USD	+2.66%		-0.65%	-29.80%

Apr. 22	Corcept Therapeutics Incorporated Announces Positive Results from Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients with Cushing?s Syndrome	CI
Apr. 15	Corcept Completes Enrollment in Phase 2 Dazals Trial in Patients with Amyotrophic Lateral Sclerosis	CI

Corcept Therapeutics Incorporated Provides Revenue Guidance for the Year 2024

February 15, 2024 at 05:00 pm EST

Corcept Therapeutics Incorporated provided revenue guidance for the year 2024. The company expects revenue growth to continue and are reiterating 2024 revenue guidance of $600 million to $630 million compared to 2023 revenue of $482.4 million.

Latest news about Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated Announces Positive Results from Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients with Cushing?s Syndrome	Apr. 22	CI
Corcept Completes Enrollment in Phase 2 Dazals Trial in Patients with Amyotrophic Lateral Sclerosis	Apr. 15	CI
Corcept Therapeutics Incorporated Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer	Apr. 08	CI
Corcept Therapeutics Incorporated Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients with Adrenal Cushing's Syndrome	Apr. 01	CI
Corcept Therapeutics Insider Sold Shares Worth $430,475, According to a Recent SEC Filing	Mar. 21	MT
Sector Update: Health Care Stocks Advance Friday Afternoon	Feb. 16	MT
Truist Securities Adjusts Price Target on Corcept Therapeutics to $42 From $36, Maintains Buy Rating	Feb. 16	MT
Sector Update: Health Care Stocks Gain Pre-Bell Friday	Feb. 16	MT
Corcept Therapeutics Q4 Net Income, Revenue Increase; Reiterates Guidance; Shares Gain Pre-Bell	Feb. 16	MT
Sector Update: Health Care	Feb. 16	MT
Corcept Therapeutics Q4 Net Income, Revenue Increase; Reiterates Guidance	Feb. 15	MT
Corcept Therapeutics Incorporated Provides Revenue Guidance for the Year 2024	Feb. 15	CI
Transcript : Corcept Therapeutics Incorporated, Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Corcept Therapeutics Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Corcept Therapeutics Incorporated Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15	CI
Corcept Therapeutics Incorporated Announces Preliminary Results from Prevalence Phase of CATALYST Clinical Trial	Feb. 15	CI
Corcept Therapeutics Incorporated Appoints Roberto Vieira as President, Oncology	Jan. 29	CI
Corcept Therapeutics Sees 31% Increase in Q4 Revenue, Issues 2024 Revenue Guidance	Jan. 08	MT
Corcept Therapeutics Incorporated announces an Equity Buyback for $200 million worth of its shares.	Jan. 08	CI
Corcept Therapeutics Incorporated Provides Revenue Guidance for the Year 2024	Jan. 08	CI
Corcept Therapeutics Incorporated authorizes a Buyback Plan.	Jan. 07	CI
HC Wainwright Adjusts Corcept Therapeutics' Price Target to $28 From $34, Keeps Buy Rating	Jan. 02	MT
Top Midday Decliners	Jan. 02	MT
Wall Street Set to Open 2024 Lower Amid Rise in Oil Prices, Ahead of Manufacturing, Construction Data	Jan. 02	MT
Sector Update: Health Care Stocks Decline Pre-Bell Tuesday	Jan. 02	MT

Chart Corcept Therapeutics Incorporated

Duration

Period

More charts

Company Profile

Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Companyâs portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.

Sector

Pharmaceuticals

Calendar

2024-05-01 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Corcept Therapeutics Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

22.8 USD

Average target price

42.8 USD

Spread / Average Target

+87.72%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CORCEPT THERAPEUTICS INCORPORATED	-29.80%	2.37B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals